Review of development program led to reassessment of benefit-risk ratio in all four potential indications for the investigational P2X3 receptor antagonist

BERLIN, Germany I February 4, 2022 I Bayer today announced the discontinuation of Phase II development candidate eliapixant (BAY 1817080), an investigational P2X3 receptor antagonist that was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.

Eliapixant is an investigational agent and has not been approved for use in any country, for any indication.

Eliapixant was derived from Bayer’s strategic alliance with Evotec SE, a global drug discovery and development company. Bayer continues to collaborate with Evotec on other research and development programs.

Bayer remains fully committed to research and development of new treatment options for patients with high unmet medical needs.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to Find more information at